Understanding the publication status of research findings is an important part of scientific literacy, and the concept of an Article in Press deserves careful explanation for readers who encounter early-access manuscripts online. When a manuscript passes peer review at a journal such as BMC Pharmacology and Toxicology, it is formally accepted by the editors on behalf of the journal, but the journey from acceptance to final publication involves several additional production steps. Copyediting, typesetting, author proofing, and quality checks all take time, and journals have increasingly chosen to make accepted manuscripts visible during this interval rather than withholding them until the final version is ready. The result is the Article in Press: a version of record in waiting that carries a permanent Digital Object Identifier and can therefore be viewed, shared, and cited immediately, even though further editorial refinement may still occur before the definitive Version of Record appears.

The Digital Object Identifier plays a central role in this system. A DOI is a persistent alphanumeric string assigned to a scholarly work that resolves to a stable landing page, regardless of where the content is hosted or how the surrounding website changes over time. Because the Article in Press receives its DOI at the moment of acceptance, any citation made to the early version will continue to resolve correctly after the final Version of Record replaces it, since the DOI is retained across the transition. This design decision reflects a broader shift in scholarly publishing toward treating the accepted manuscript as a citable scientific contribution in its own right, rather than as a preliminary draft that must remain hidden until production is complete. For researchers who build on new findings quickly, particularly in fast-moving fields such as pharmacology and toxicology where timely access to dose-response data, safety signals, and mechanistic results can influence ongoing studies, the interval between acceptance and final publication can be scientifically meaningful.

Readers should nonetheless understand what the Article in Press label signals about the maturity of the text. Errors affecting the content may be discovered during the final production process, and corrections identified at this stage are incorporated during author proofing, the step in which authors review the typeset version of their manuscript and mark any necessary changes. The Version of Record that ultimately replaces the Article in Press is the definitive, fully produced article, and it is the version against which future corrections, retractions, or editorial expressions of concern would formally be logged. The early-access version is clearly labelled online to make this distinction visible, which helps readers, indexers, and citation databases avoid confusion about which iteration of a paper they are consulting. All legal disclaimers that apply to the journal also apply to Articles in Press, meaning that the same standards governing the final article govern the early version as well.

This publication model is closely tied to the open access movement. Fully open access journals make every accepted manuscript available at the Article in Press stage, ensuring that no paywall or production delay separates the scientific community from peer-reviewed findings once acceptance has occurred. The economics of open access publishing, in which article processing charges or institutional agreements cover the costs of publication rather than subscription fees, make this rapid-release model feasible: because revenue does not depend on controlling access to the finished product, there is no commercial reason to withhold accepted work. For pharmacology and toxicology specifically, this can matter in practical terms. Findings concerning drug safety, toxicological mechanisms, adverse effect profiles, and therapeutic interactions are often of immediate interest to clinicians, regulators, and other researchers, and narrowing the window between acceptance and visibility serves those audiences directly.

The specific article at issue here appears in the Articles in Press feed of BMC Pharmacology and Toxicology, a peer-reviewed journal that publishes research spanning the pharmacological and toxicological sciences. Work in this field commonly addresses how chemical compounds interact with biological systems at the level of molecular targets, cellular pathways, whole organisms, and populations. Studies may range from preclinical investigations of drug mechanisms and toxicity pathways to evaluations of therapeutic outcomes and safety pharmacology. The journal’s scope reflects the substantial overlap between pharmacology and toxicology as disciplines: a compound’s therapeutic window is defined by the relationship between the doses that produce benefit and the doses that produce harm, and research in either field frequently informs the other. Readers consulting the Articles in Press feed should therefore expect a steady stream of newly accepted manuscripts covering this breadth, each carrying the caveats described above about its provisional editorial status.

One practical consequence of the Article in Press model concerns how such manuscripts should be cited. Because the DOI is assigned at acceptance and persists through the transition to the Version of Record, citations made to the early version remain valid indefinitely. However, the content of the final published version may differ in small ways from the Article in Press, since author proofing can correct typographical errors, clarify ambiguous passages, and fix substantive mistakes discovered during production. Scholars who rely heavily on a particular early-access manuscript, for example by reproducing a specific numerical result or quoting a methodological detail, may wish to verify those details against the final Version of Record once it appears. Most modern reference managers and publisher platforms handle this transition automatically, updating citation records when the final version is published, but individual vigilance remains worthwhile for claims that carry particular weight in downstream work.

The existence of an Articles in Press feed also illustrates how journals communicate their editorial pipeline to the public. By maintaining a continuously updated list of accepted manuscripts, the journal signals both its throughput and its transparency: readers can see that peer review has concluded and that the work has met the journal’s bar for acceptance, even before the polished final article is available. This visibility can be particularly valuable for systematic reviewers and meta-analysts, who are often advised to search for articles in press and early-access material to reduce publication bias and to capture the most current evidence. It can also benefit the authors themselves, whose accepted work becomes visible and citable months earlier than would otherwise be possible, a factor that can matter for grant reporting, thesis completion, and career progression.

Press releases represent another area where the Article in Press stage has practical implications. Journals that support press outreach for accepted manuscripts typically ask authors and institutions to coordinate with the production editor as early as possible, because embargoes, timing, and the availability of the citable version all need to be aligned. A press release issued before the Article in Press is live risks directing journalists to a manuscript that cannot yet be accessed or cited, while a release issued after the final Version of Record appears may miss the window of peak news interest. Coordinating early allows the journal, the authors, and institutional communications offices to synchronize the release of the story with the moment the citable early version becomes publicly available, maximizing both accuracy and impact.

For readers evaluating any Article in Press, a few habits of critical appraisal remain as important as they are for final published articles. Peer review, however rigorous, is a process of expert scrutiny rather than a guarantee of truth, and the replication crisis documented across the biomedical sciences has underscored the value of independent confirmation, transparent data, and careful attention to statistical methods. Early-access status adds one more layer of provisional character: the text may still be refined, and any errors identified during production will be corrected in the final version. Readers should therefore treat the Article in Press as a legitimate, citable scientific contribution while remaining aware that the definitive Version of Record is the version against which the scholarly record will ultimately be judged. Checking the journal’s labeling, noting the DOI, and revisiting the article after final publication are simple practices that keep one’s citations accurate and one’s understanding of the evidence current.

Finally, the mechanics described here reflect broader trends in scholarly communication that extend well beyond a single journal. The movement toward continuous publication, in which articles appear online as soon as they are ready rather than being gathered into discrete issues, has blurred the traditional boundaries of the journal volume and made early access the norm rather than the exception at many publishers. Persistent identifiers such as the DOI, alongside ORCID identifiers for authors and increasingly granular metadata standards, underpin this ecosystem by ensuring that each version of a work can be located, linked, and cited unambiguously. For the pharmacology and toxicology community, whose findings feed directly into drug development, regulatory assessment, and clinical practice, the ability to access and cite peer-reviewed work at the moment of acceptance, with the assurance that the citation will remain stable through to the final Version of Record, represents a meaningful improvement in how scientific knowledge circulates. The Articles in Press mechanism, with its clear labeling, retained DOI, and defined correction pathway, is a small but consequential piece of that larger infrastructure, and understanding how it works helps readers navigate the modern scientific literature with appropriate confidence and appropriate caution.

Subject of Research: Early-access publishing workflow for peer-reviewed articles

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, open access, digital object identifier, version of record, scientific publishing, Springer Nature, BMC Pharmacology and Toxicology, author proofing, scholarly communication, Articles, Press